Webinar on CMS and Affordable Care Act:First of a series of AMCP Member Regulatory Briefings providing an overview of newly proposed regulations and agency guidance relevant to managed care pharmacy Watch RecordingClose
Resources for students such as educational tools covering a variety of managed care topics and information on professional opportunities (internships, APPEs, fellowships and residencies) related to managed care pharmacy.
On March 27, 2025, the U.S. Department of Health and Human Services (HHS) issued a Fact Sheet: HHS’ Transformation to Make America Healthy Again. The document outlines HHS' restructuring plan as part of an initiative to enhance efficiency and address chronic diseases in America. Key changes include significant personnel reductions and consolidating divisions and offices to streamline operations.
AMCP formed the PAC to support candidates who promote policies that improve the practice of managed care pharmacy. Prescription drug prices consistently rank as a top issue for voters, so it’s important to ensure that the managed care perspective is represented in these policy conversations.
A coalition of 34 scientific and medical organizations led by the American Association of Immunologists and the American College of Physicians released the following statement.
A new Academy of Managed Care Pharmacy Foundation report, “Emerging Trends Impacting Managed Care Pharmacy,” developed in partnership with Pfizer, warned of significant shifts within managed care pharmacies fueled by AI adoption, drug shortages and affordability challenges.
The Protecting Pharmacies in Medicaid Act would prohibit the use of spread pricing arrangements in Medicaid programs. Pharmacy benefit managers (PBMs) would be required to pass through to pharmacies the full amount of the money paid to the PBMs by Medicaid programs, except for a fixed administrative fee. The total reimbursement amount will be determined by a survey of national average drug acquisition costs administered by the Department of Health & Human Services.
On March 12, 2025, the Centers for Medicare & Medicaid Services (CMS) Innovation Center announced the early termination of several payment model trials by December 31, 2025.
In AMCP's latest comments to the FDA, we emphasize the need for standardized public reporting of confirmatory trial progress, ensuring payers and health care providers have the necessary data to make informed coverage decisions. By supporting proactive communication and rigorous confirmatory trials, AMCP aims to balance early access to innovative treatments with patient safety and long-term therapeutic value.
Over the weekend, Congressional leadership released a continuing resolution (CR) that extends government funding at the same level as the previous fiscal year, through September 30. Congress must extend government funding by March 14 to avoid a government shutdown.